These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36449662)

  • 21. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab in Solid Tumors.
    Chen M; Jiang J; Chen J; Wang M; Lu Y; Liu L; Zhao L; Wang L
    Curr Drug Targets; 2023; 24(7):584-598. PubMed ID: 36998143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Gallium-68-Labeled Peptide Radiotracer For CD38-Targeted Imaging In Multiple Myeloma With PET.
    Sharma AK; Gupta K; Mishra A; Lofland G; Marsh I; Kumar D; Ghiaur G; Imus P; Hobbs RF; Gocke CB; Nimmagadda S
    bioRxiv; 2023 Oct; ():. PubMed ID: 37214794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development, Characterization, and Radiation Dosimetry Studies of
    Kim J; Donnelly DJ; Tran T; Pena A; Shorts AO; Petrone TV; Zhang Y; Boy KM; Scola PM; Tenney DJ; Poss MA; Soars MG; Bonacorsi SJ; Cole EL; Grootendorst DJ; Chow PL; Meanwell NA; Du S
    Mol Imaging Biol; 2024 Apr; 26(2):301-309. PubMed ID: 38123744
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D
    Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
    Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
    J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
    Zajac M; Boothman AM; Ben Y; Gupta A; Jin X; Mistry A; Sabalos C; Nielsen A; Manriquez G; Barker C; Antal J; Wang P; Patil P; Schechter N; Rebelatto MC; Walker J
    Arch Pathol Lab Med; 2019 Jun; 143(6):722-731. PubMed ID: 30457897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of
    Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C
    J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel
    Ge S; Zhang B; Li J; Shi J; Jia T; Wang Y; Chen Z; Sang S; Deng S
    Bioorg Chem; 2023 Nov; 140():106785. PubMed ID: 37639759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical and first-in-human evaluation of
    Zhou M; Wang X; Chen B; Xiang S; Rao W; Zhang Z; Liu H; Fang J; Yin X; Deng P; Zhang X; Hu S
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4312-4324. PubMed ID: 35831714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET Imaging of Peptide Probe Al[
    Zhang Y; Wang Y; Chen Y; Ding X; Wang S; Liu W; Hu M; Liu Z
    Mol Pharm; 2024 Mar; 21(3):1515-1525. PubMed ID: 38291578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
    Faiena I; Cummings AL; Crosetti AM; Pantuck AJ; Chamie K; Drakaki A
    Drug Des Devel Ther; 2018; 12():209-215. PubMed ID: 29416316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noninvasive PET imaging of tumor PD-L1 expression with
    Malih S; Lin W; Tang Z; DeLuca MC; Engle JW; Alirezapour B; Cai W; Rasaee MJ
    Am J Nucl Med Mol Imaging; 2024; 14(1):31-40. PubMed ID: 38500749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging.
    Li D; Wang F; Jiang J; Hou X; Ding J; Wang Z; Chen Y; Liu T; Yang Z; Zhu H
    Mol Pharm; 2022 Nov; 19(11):4382-4389. PubMed ID: 36268880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
    Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
    Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer
    Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN
    J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092
    [No Abstract]   [Full Text] [Related]  

  • 38. PD-L1 detection using
    Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
    J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The discovery and evaluation of [
    Donnelly DJ; Kim J; Tran T; Scola PM; Tenney D; Pena A; Petrone T; Zhang Y; Boy KM; Poss MA; Cole EL; Soars MG; Johnson BM; Cohen D; Batalla D; Chow PL; Shorts AO; Du S; Meanwell NA; Bonacorsi SJ
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):978-990. PubMed ID: 38049658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
    Chatterjee S; Lesniak WG; Miller MS; Lisok A; Sikorska E; Wharram B; Kumar D; Gabrielson M; Pomper MG; Gabelli SB; Nimmagadda S
    Biochem Biophys Res Commun; 2017 Jan; 483(1):258-263. PubMed ID: 28025143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.